...
首页> 外文期刊>Journal of Drug Delivery and Therapeutics >Development and Characterization of Mucoadhesive Nanoparticles of Topiramate for Nasal Administration
【24h】

Development and Characterization of Mucoadhesive Nanoparticles of Topiramate for Nasal Administration

机译:鼻腔给药托吡酯黏膜粘附纳米颗粒的开发与表征

获取原文

摘要

Nasal drug delivery has been recognized as a promising route for delivery of therapeutic compounds including biopharmaceuticals. It has been demonstrated that absorption of drugs can enhance by using absorption enhancers or increasing the drug residence time in the nasal cavity. Mucoadhesive polymers can serve both functions. The residence time in the nasal cavity is considerably increased for nanoparticles compared to solutions. Topiramate (TPM)?is used alone or with other medications to prevent and control seizures (epilepsy). This medication is also used to prevent migraine headaches and decrease how often you get them.?TPM will not treat a migraine headache once it occurs. The purpose of the present study was to prepare and evaluate mucoadhesive chitosan nanoparticles of TPM for the nasal administration by ionic gelation method. Nanoparticles were subjected to various characterization techniques such as FTIR, particle size, scanning electron microscopy (SEM), drug entrapment efficiency and zeta potential are also determined for the developed formulations. The nanoparticles exhibited mucoadhesive properties, which diminished with increasing drug content. The nanoparticles with a particle size range between 45and 62nm exhibited excellent mucoadhesive properties. Stability study at various storage temperature was also done in which the prepared formulation showed an improved stability. The zeta potential of the best chitosan preparation (F4) was found to be -35.5mV, which confirms the stability of prepared nanosuspension. Mucoadhesive chitosan nanoparticles can be a promising carrier for nasal delivery of TPM found to have high encapsulation efficiency and predetermined in vitro release profile.
机译:鼻药物递送已被认为是包括生物药物在内的治疗化合物递送的有希望的途径。已经证明可以通过使用吸收促进剂或增加药物在鼻腔中的停留时间来增强药物的吸收。粘膜粘附性聚合物可以起到两种作用。与溶液相比,纳米颗粒在鼻腔中的停留时间大大增加。托吡酯(TPM)?可单独使用或与其他药物一起使用,以预防和控制癫痫发作(癫痫)。该药物还可用于预防偏头痛,并减少您的头痛发作频率。TPM一旦发生偏头痛,将无法治疗。本研究的目的是通过离子凝胶法制备和评价用于鼻腔给药的TPM粘膜粘附性壳聚糖纳米颗粒。纳米颗粒还经历了各种表征技术,例如FTIR,粒径,扫描电子显微镜(SEM),药物包封效率和Zeta电位,这些都已确定出来。纳米颗粒表现出粘膜粘附特性​​,随着药物含量的增加而降低。粒径范围在45至62nm之间的纳米颗粒表现出优异的粘膜粘附特性​​。还进行了在各种储存温度下的稳定性研究,其中制备的制剂显示出改善的稳定性。发现最佳的壳聚糖制剂(F4)的Zeta电位为-35.5mV,这证实了所制备的纳米悬浮液的稳定性。粘膜粘附性壳聚糖纳米颗粒可以作为TPM经鼻输送的有希望的载体,被发现具有高封装效率和预定的体外释放特性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号